Cancer of the blood or the bone marrow is known as leukemia. It is caused when the damage to the genetic material of immature blood cells, mainly white blood cells, results in the continuous formation of new abnormal blood cells. The healthy blood cells die in time, but these abnormal blood cells do not die and get accumulated.
Moxetumomab Pasudotox-Tdfk: Uses, Dosage, Precautions, Side Effects, and Pharmacological Aspects
Moxetumomab pasudotox-tdfk treats relapsed or refractory hairy cell leukemia by targeting CD22 on B-cells and delivering a cytotoxin to kill cancer cells.
CRISPR Technology in Hematology - An Overview
Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) technology is a modern genetic technology developing particularly in hematology.
Tirabrutinib for B-cell Malignancies - Indication, Uses, Side Effects
Tirabrutinib is used to treat B-cell malignancies. Read further to know in detail.
Pentostatin - A Cutting-Edge Weapon Against Hairy Cell Leukemia
Pentostatin is a medication used for treating hairy cell leukemia by inhibiting adenosine deaminase.
Induction Therapy for Leukemia
Induction therapy, a critical phase in leukemia treatment, employs intensive chemotherapy and targeted therapies to achieve complete remission.
Juvenile Myelomonocytic Leukemia - An Overview
Children with juvenile myelomonocytic leukemia, usually those four years of age and younger, are affected by this uncommon kind of chronic leukemia.
Leukemia vs. Lymphoma: Decoding the Differences
Leukemia and lymphoma are both hematologic malignancies originating from lymphoid tissues.
Genetics and Molecular Basis of Leukemia - Insights Into Pathogenesis
Leukemia is the abnormal multiplication of immature white blood cells that impair the body's capacity to resist infections and perform typical roles.
Down Syndrome-Associated Leukemias - An Overview
Down syndrome-associated leukemia poses unique challenges due to genetic predisposition, requiring tailored treatment strategies for optimal outcomes.
Gemtuzumab Ozogamicin: A Game-Changer in AML Treatment
Gemtuzumab ozogamicin injection treats acute myeloid leukemia by targeting leukemia cells.
